The Global CGMS Market $589 million in 2015, and is projected to reach $6,238 million by 2022, registering a CAGR of approximately 39.9% from 2016 to 2022.
Real-time continuous glucose monitoring is of utmost importance across all age groups to manage diabetes effectively. Continuous glucose monitoring system (CGMS) enables effective managing of blood glucose levels by providing trend data as well as alarms for the fluctuations in glucose levels.
Diabetes, a chronic lifestyle disease, is classified into type 1 and type 2 diabetes. In type 1 diabetes, the pancreas is unable to produce sufficient or requisite amount of insulin hormone, which is required for the breakdown of glucose. It is prevalent in children or young adults and as per the global estimates of International Diabetes Federation (IDF), in 2015, Type 1 diabetes has affected around 542,100 children in the age group below 15 years. Whereas, in type 2 diabetes, the pancreas produce insulin, but the cells do not respond and/or lack the ability to uptake the insulin available in the blood stream. It is the most prevalent type of diabetes, affecting around 8% share of the global population in the age group of 2079 years, which accounts for more than 95% of all types of diabetes.
Argentina CGMS devices market is projected to grow at a high CAGR of 43.9% during the forecast period, generating revenue of $3,818 thousand by 2022. The lack of awareness and issues pertaining to price constraints could restrain the market growth. However, supportive government policies, such as spreading awareness and funding or reimbursement for CGM devices would boost the growth of the CMGS market in Argentina.
KEY BENEFITS FOR STAKEHOLDERS:
CGM MARKET KEY SEGMENTS:
The CGMS market is segmented based on component, end user segment, end user demographics, and geography (country-level analysis).
By Component
By Demographics
By End User
By Geography
CHAPTER 1 INTRODUCTION
1.1. Report Description
1.2. Key Benefits
1.3. Key Market Segments
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3 MARKET OVERVIEW
3.1. Market definition
3.2. Need for glucose monitoring systems
3.2.1. Diabetesa pandemic
3.2.1.1. Type 1 diabetes
3.2.1.2. Type-2 diabetes
3.2.1.3. Prediabetes and gestational diabetes mellitus (GDM)
3.2.1.4. Gestational diabetes mellitus (GDM)
3.2.1.5. Secondary diabetes
3.2.1.6. Global healthcare expenditure on diabetes
3.3. Technological Advancements IN CGMS
3.3.1.1. Smartphone-connected CGMS
3.3.1.2. Wearable and smartphone-connected CGMS
3.3.1.3. 'Smart diabetes management solutionbionic/artificial pancreas
3.3.1.4. Non-invasive CGMS
3.3.1.5. Invasive CGMS
3.3.2. CGMS: PRIME END USER SEGMENTS
3.3.2.1. CGMS: role in intensive care units (ICUs)
3.3.2.1.1. STRESS HYPERGLYCEMIA: COMMON OCCURRENCE IN ICUS
3.3.2.2. Non-standardization and erroneous glycemic control across ICUs
3.3.2.3. Benefits and driving factors of CGMS in ICUs
3.3.2.3.1. USE OF CGMS FOR TIGHT GLYCEMIC CONTROL IN ICUS
3.3.2.3.2. COST BENEFITS DUE TO USE OF CGMS
3.3.2.3.3. LOWER EFFECTIVENESS OF POC GLUCOMETERS THAN CGMS IN ICUS
3.3.2.3.4. CGMS: MOST PREFERRED BY ICU STAFF
3.4. Key Findings
3.4.1. Top investment pockets
3.4.1.1. CGMS market, by components
3.4.2. Top winning strategies
3.5. Value Chain Analysis
3.6. Patent Analysis
3.6.1. Patent analysis, by market participant
3.6.2. U.S. patent analysis, by market participant
3.6.3. Patent analysis, by year
3.7. Market Share Analysis, 2015
3.8. Government Regulations
3.8.1. FDA regulations (21CFR820)
3.8.1.1. Objective and Scope of FDA 21CFR820
3.8.2. ISO regulations (ISO 13485:2003)
3.8.2.1. Objective and Scope of ISO 13485:2003
3.9. Europe Reimbursement Scenario
3.9.1. Germany
3.9.2. France
3.9.3. UK
3.9.4. Spain
3.9.5. Italy
3.10. Market dynamics
3.10.1. Drivers
3.10.1.1. Benefits of CGMS over POC glucometers
3.10.1.2. Rise in incidence of diabetes cases
3.10.1.3. Technological advancements
3.10.2. Restraints
3.10.2.1. Adverse effects and accuracy
3.10.2.2. Reimbursement and stringent regulatory issues
3.10.3. Opportunities
3.10.3.1. High adoption rate of CGMS in home healthcare and ICUs
3.10.3.2. Increase in product awareness
3.10.3.3. High undiagnosed patient population
CHAPTER 4 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENT
4.1. Overview
4.1.1. Market size and forecast
4.2. Sensors
4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast
4.2.3.1. Non-invasive glucose sensors
4.2.3.2. Subcutaneous sensors (Minimally Invasive Sensors)
4.2.3.3. Conventional technologyHolter-type retrospective sensors
4.2.3.4. Advanced technologyReal-time sensors
4.3. Transmitters & Receivers
4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast
4.4. Integrated Insulin pumps
4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast
CHAPTER 5 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKETBY DEMOGRAPHICS
5.1. Overview
5.1.1. Market size and forecast
5.2. Adult Population (>14 years)
5.2.1. Market size and forecast
5.3. Children Population (14 years)
5.3.1. Market size and forecast
CHAPTER 6 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Diagnostic centers/clinics
6.2.1. Market size and forecast
6.2.2. Reimbursement scenario
6.3. ICUs
6.3.1. Market size and forecast
6.4. Home Healthcare
6.4.1. Market size and forecast
CHAPTER 7 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY GEOGRAPHY
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast
7.2.4. U.S.
7.2.5. Canada
7.2.6. Mexico
7.3. Europe
7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast
7.3.4. Germany
7.3.5. France
7.3.6. UK
7.3.7. Spain
7.3.8. Italy
7.3.9. Netherlands
7.3.10. Norway
7.3.11. Sweden
7.3.12. Denmark
7.3.13. Finland
7.3.14. Rest of Europe
7.4. Asia-Pacific
7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast
7.4.4. India
7.4.5. Australia
7.4.6. China
7.4.7. Japan
7.4.8. South Korea
7.4.9. Rest of Asia-Pacific
7.5. LAMEA
7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast
7.5.4. Brazil
7.5.5. Saudi Arabia
7.5.6. South Africa
7.5.7. Venezuela
7.5.8. Argentina
7.5.9. Rest of LAMEA
CHAPTER 8 COMPANY PROFILES
8.1. Abbott laboratories
8.1.1. Overview
8.1.2. ABBOTT: company snapshot
8.1.3. Operating business segments
8.1.4. Abbott: operating segments
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. Dexcom, inc.
8.2.1. Overview
8.2.2. DexCom: company snapshot
8.2.3. Business performance
8.2.4. Key strategic moves and developments
8.3. Echo Therapeutics, Inc.
8.3.1. Overview
8.3.2. Echo Therapeutics: company snapshot
8.3.3. Business performance
8.3.4. Key strategic moves and developments
8.4. Glysens Incorporated
8.4.1. Overview
8.4.2. GlySens: company snapshot
8.4.3. Key strategic moves and developments
8.5. Insulet Corporation
8.5.1. Overview
8.5.2. Insulet: company snapshot
8.5.3. Business performance
8.5.4. Key strategic moves and developments
8.6. Johnson & Johnson
8.6.1. Overview
8.6.2. JnJ: company snapshot
8.6.3. Operating business segments
8.6.4. JNJ: operating segments
8.6.5. Business performance
8.6.6. Key strategic moves and developments
8.7. Medtronic plc
8.7.1. Overview
8.7.2. Medtronic: company snapshot
8.7.3. Operating business segments
8.7.4. Medtronic: operating segments
8.7.5. Business performance
8.7.6. Key strategic moves and developments
8.8. Senseonics Holdings, Inc.
8.8.1. Overview
8.8.2. Senseonics: company snapshot
8.8.3. Key strategic moves and developments
8.9. F. HOFFMANN-LA ROCHE LTD.
8.9.1. Overview
8.9.2. Roche: company snapshot
8.9.3. Business performance
8.9.4. Key strategic moves and developments
The other companies in the CGMS market include:
*Profiles of these players are not included. The same will be included on request.
LIST OF TABLES
TABLE 1. FEATURES OF CURRENTLY AVAILABLE STAND-ALONE CGM SYSTEMS (2016)
TABLE 2. FEATURES OF CURRENTLY AVAILABLE INTEGRATED CGM SYSTEMS (2016)
TABLE 3. GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS, 2014-2022 ($THOUSAND)
TABLE 4. GLOBAL CONTINUOUS GLUCOSE MONITORING SENSORS MARKET, BY REGION, 2014-2022 ($THOUSAND)
TABLE 5. GLOBAL CONTINUOUS GLUCOSE MONITORING TRANSMITTERS AND RECEIVERS MARKET, BY REGION, 2014-2022 ($THOUSAND)
TABLE 6. GLOBAL CONTINUOUS GLUCOSE MONITORING INTEGRATED INSULIN PUMPS MARKET, BY REGION, 20142022 ($THOUSAND)
TABLE 7. GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHICS, 2014-2022 ($THOUSAND)
TABLE 8. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR ADULT POPULATION (>14YEARS), BY REGION, 2014-2022 ($THOUSAND)
TABLE 9. TYPE-1 DIABETES (014 YEARS), 2015
TABLE 10. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET CHILD POPULATION (14YEARS), BY REGION, 2014-2022 ($THOUSAND)
TABLE 11. GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2014-2022 ($THOUSAND)
TABLE 12. DIAGNOSTICS/CLINICS CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY REGION, 2014-2022 ($THOUSAND)
TABLE 13. ICUS CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY REGION, 2014-2022 ($THOUSAND)
TABLE 14. ICUS CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY REGION, 2014-2022 ($THOUSAND)
TABLE 15. TOP FACTORS IMPACTING GLOBAL CGMS MARKET IN 2015 AND 2022, BY GEOGRAPHY
TABLE 16. TOP 10 COUNTRIES WITH DIABETES INCIDENCE (2079 YEARS), 2015 AND 2040
TABLE 17. GLOBAL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY REGION, 2014-2022 ($THOUSAND)
TABLE 18. NORTH AMERICA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS, 2014-2022 ($THOUSAND)
TABLE 19. NORTH AMERICA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHICS, 2014-2022 ($THOUSAND)
TABLE 20. NORTH AMERICA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2014-2022 ($THOUSAND)
TABLE 21. NORTH AMERICA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COUNTRY, 2014-2022 ($THOUSAND)
TABLE 22. PREVALENCE ESTIMATES OF DIABETES (2079 YEARS) IN EUROPE, 2015
TABLE 23. EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS, 2014-2022 ($THOUSAND)
TABLE 24. EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHICS, 2014-2022 ($THOUSAND)
TABLE 25. EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2014-2022 ($THOUSAND)
TABLE 26. EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COUNTRY, 2014-2022 ($THOUSAND)
TABLE 27. MEDICAL DEVICES USED IN AUSTRALIA
TABLE 28. ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS, 2014-2022 ($THOUSAND)
TABLE 29. ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHICS, 2014-2022 ($THOUSAND)
TABLE 30. ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2014-2022 ($THOUSAND)
TABLE 31. ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COUNTRY, 2014-2022 ($THOUSAND)
TABLE 32. LAMEA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS, 2014-2022 ($THOUSAND)
TABLE 33. LAMEA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHICS, 2014-2022 ($THOUSAND)
TABLE 34. LAMEA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2014-2022 ($THOUSAND)
TABLE 35. LAMEA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COUNTRY, 2014-2022 ($THOUSAND)
LIST OF FIGURES
FIGURE 1. PREVALENCE OF TYPE 1 DIABETES (AGE GROUP OF <15 YEARS), BY GEOGRAPHY (2015)
FIGURE 2. GLOBAL PREVALENCE OF TYPE-2 DIABETES (2014)
FIGURE 3. SIMILAR PREDISPOSITION AND RISK FACTORS FOR PREDIABETES AND TYPE-2 DIABETES
FIGURE 4. TOP TEN COUNTRIES/TERRITORIES FOR DIABETES-RELATED HEALTH EXPENDITURE, 2015
FIGURE 5. GLOBAL FINANCIAL BURDEN OF DIABETES, BY GEOGRAPHY
FIGURE 6. OCCURRENCE OF HYPERGLYCEMIA IN ICUS
FIGURE 7. TOP INVESTMENT POCKETS IN CGMS, BY COMPONENTS SEGMENT
FIGURE 8. TOP WINNING STRATEGIES IN CGMS MARKET: PERCENTAGE DISTRIBUTION (20142016)
FIGURE 9. TOP WINNING STRATEGIES IN CGMS MARKET: NATURE AND TYPE (20142016)
FIGURE 10. VALUE CHAIN OF GLOBAL CGMS MARKET
FIGURE 11. PATENTS REGISTERED/APPROVED IN THE WORLD THROUGH 2016
FIGURE 12. PATENT ANALYSIS BY MARKET PARTICIPANT, 20102016
FIGURE 13. U.S.: PATENT ANALYSIS BY MARKET PARTICIPANT, 2010 THROUGH 2016
FIGURE 14. PATENTS ANALYSIS BY YEAR, 2010 THROUGH 2016
FIGURE 15. MARKET SHARE ANALYSIS OF GLOBAL CGMS MARKET, 2015
FIGURE 16. UNDIAGNOSED PATIENT POPULATION OF DIABETES, 2015 (MILLION)
FIGURE 17. TOP IMPACTING FACTORS OF GLOBAL CGMS MARKET, 2015 AND 2022
FIGURE 18. U.S. CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 19. CANADA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 20. MEXICO CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 21. GERMANY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 22. FRANCE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 23. UK CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 24. SPAIN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 25. ITALY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 26. NETHERLANDS CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 27. NORWAY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 28. SWEDEN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 29. DENMARK CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 30. FINLAND CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 31. REST OF EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 32. INDIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 33. AUSTRALIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 34. CHINA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 35. JAPAN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 36. SOUTH KOREA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 37. REST OF ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 38. BRAZIL CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 39. SAUDI ARABIA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 40. SOUTH AFRICA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 41. VENEZUELA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 42. ARGENTINA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 43. REST OF LAMEA CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
FIGURE 44. ABBOTT: REVENUE, BY YEAR ($MILLION)
FIGURE 45. ABBOTT: REVENUE, BY SEGMENT, 2015 (%)
FIGURE 46. ABBOTT: REVENUE, BY GEOGRAPHY, 2015 (%)
FIGURE 47. DEXCOM: REVENUE, BY YEAR ($MILLION)
FIGURE 48. DEXCOM: REVENUE, BY GEOGRAPHY, 2015 (%)
FIGURE 49. ECHO THERAPEUTICS: REVENUE, BY YEAR ($MILLION)
FIGURE 50. INSULET: REVENUE, BY YEAR ($MILLION)
FIGURE 51. JNJ: REVENUE, BY YEAR ($MILLION)
FIGURE 52. JNJ: REVENUE, BY SEGMENT, 2015 (%)
FIGURE 53. JNJ: REVENUE, BY GEOGRAPHY, 2015 (%)
FIGURE 54. MEDTRONIC: REVENUE, BY YEAR ($MILLION)
FIGURE 55. MEDTRONIC: REVENUE BY SEGMENT, 2016 (%)
FIGURE 56. MEDTRONIC: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 57. ROCHE: REVENUE, BY YEAR ($MILLION)
FIGURE 58. ROCHE: REVENUE, BY GEOGRAPHY, 2015 (%)
Contact us at the Consulting WP office nearest to you or submit a business inquiry online.
Subscribe to Our Newsletter
Published On : December 2019
$ 3600
Published On : December 2019
$ 3600
